VRTX Gap Fill Play - Bullish
- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis.
- Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts
- Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact.
- Price entering the gap from that day's drop.
- Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued.
- Bull flagging right under the gap.
Key Level: $232.41
Price Target: 269.93
ATR: $6.60
Play:
Bullish Gap Fill
Buy the Dip under the key level to scale in
Use $232.41 as inflection point.
Look for breakout with increased volume
Price Target: 270
Under $224 will invalidate
- Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts
- Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area and fundamentals of other revenue makers intact.
- Price entering the gap from that day's drop.
- Trends of more insider buying since the drop and stock buy backs. Signaling that the stock is undervalued.
- Bull flagging right under the gap.
Key Level: $232.41
Price Target: 269.93
ATR: $6.60
Play:
Bullish Gap Fill
Buy the Dip under the key level to scale in
Use $232.41 as inflection point.
Look for breakout with increased volume
Price Target: 270
Under $224 will invalidate
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.